FinBERT, a financial-language model, scores this headline as positive (85% confidence). That is the news tone only — not the full stock rating.
Stocks › DGX
Quest Diagnostics Inc (DGX) stock analysis
WEAK BUY 21% confidence · analysed Oct 30, 2026
On Oct 30, 2026, our model rated Quest Diagnostics Inc (DGX) WEAK BUY with 21% confidence at a price of $251.38. That means the signals lean positive, but they are mixed, so conviction is low.
Analysed price$251.38
Technical picture
The 14-day RSI is 75, above 70, which is overbought: buyers have been very aggressive and a pause or pullback is common from here.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is only 0.2x its 20-day average; light trading makes the latest move less convincing.
Trend structure and money flow
Market structure shows a bullish break of structure (BOS): price broke a recent swing high in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $210.93 and the swing low is $184.79; traders often treat these as resistance and support.
Fundamentals
The PEG ratio is 1.65, which looks reasonably priced for its growth.
The company reports a profit margin of 9.5% and revenue growth of +10.0%.
In its latest quarter it earned $3.00 per share, which beat the $2.87 analysts expected, with revenue +10.0% year over year.
Wall Street's average rating is 2.1 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $257.27.
The next earnings report is expected around Feb 9, 2027; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $251.99, a target of $257.27 (+2.1%) and a stop-loss at $238.20 (-5.5%).
That is a reward-to-risk ratio of about 0.4 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Nov 9, 2026 whatever the price does.
Entry$251.99
Target$257.27
Stop-loss$238.20
Reassess byNov 9, 2026
The model's one-paragraph read
Leans BUY — composite score +0.21 (WEAK BUY). Technicals: RSI 74.53, MACD bullish, price above SMA50. Fundamentals: PEG 1.65, margin 9.5%, revenue growth 10.0%. Financial results: YoY revenue +10.0%, last EPS surprise +4.5%, next earnings 2027-02-09. Smart Money Concepts: BOS bullish (trend continuation). FinGPT news read: positive. Suggested levels: entry $251.99, target $257.27, stop-loss $238.2, exit by 2026-11-09 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for DGX
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 30, 2026 | WEAK BUY | 21% | $251.38 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on DGX
Oct 30, 2026 · Labcorp, Quest urge RESULTS Act passage as lab payment cuts loom
- Oct 30, 2026: Labcorp, Quest urge RESULTS Act passage as lab payment cuts loom (MedTech Dive)
Frequently asked questions
Is DGX a buy right now?
As of Oct 30, 2026, our automated model rates Quest Diagnostics Inc (DGX) WEAK BUY with 21% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for DGX?
The model's most recent plan targets $257.27 with a stop-loss at $238.20, from an entry near $251.99.
When does Quest Diagnostics Inc report earnings next?
The next earnings report is expected around Feb 9, 2027.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.